Drug Profile

Spirapril

Alternative Names: Cardiopril; Quadropril; Renormax; Renpress; SCH 33844; Setrilan; TI 211950

Latest Information Update: 17 Jul 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Schering-Plough
Developer Italfarmaco; Meda; Merck & Co; Novartis
Class Antihypertensives; Dipeptides; Heart failure therapies
Mechanism of Action ACE inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Heart failure; Hypertension

Most Recent Events

13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
05 Aug 2016 Meda has been acquired by Mylan
22 Aug 2000 A clinical study has been added to the Heart Failure pharmacodynamics section

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com